Abbott India
Market Cap
₹336.4b
Last Updated
2020/10/20 12:34 UTC
Data Sources
Company Financials
Executive Summary
Abbott India Limited operates as a pharmaceutical company in India. More Details
Rewards
Risk Analysis
No risks detected for 500488 from our risk checks.
Snowflake Analysis
Outstanding track record with excellent balance sheet and pays a dividend.
Similar Companies
Share Price & News
How has Abbott India's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 500488 has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-2.6%
500488
-3.2%
IN Pharmaceuticals
-0.6%
IN Market
1 Year Return
48.0%
500488
52.6%
IN Pharmaceuticals
2.2%
IN Market
Return vs Industry: 500488 underperformed the Indian Pharmaceuticals industry which returned 52.6% over the past year.
Return vs Market: 500488 exceeded the Indian Market which returned 2.2% over the past year.
Shareholder returns
| 500488 | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.6% | -3.2% | -0.6% |
| 30 Day | -4.1% | -4.3% | 0.2% |
| 90 Day | 6.0% | 13.4% | 6.7% |
| 1 Year | 50.2%48.0% | 54.5%52.6% | 3.9%2.2% |
| 3 Year | 287.5%276.2% | 26.9%23.4% | 2.6%-2.4% |
| 5 Year | 200.3%186.7% | -0.6%-4.1% | 41.3%30.8% |
Price Volatility Vs. Market
How volatile is Abbott India's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 years ago | Simply Wall St
June Top Growth Stocks To Look Out For2 years ago | Simply Wall St
Does Abbott India Limited's (BOM:500488) PE Ratio Signal A Selling Opportunity?2 years ago | Simply Wall St
Top Growth Stocks in MarchValuation
Is Abbott India undervalued compared to its fair value and its price relative to the market?
51.25x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 500488 (₹15830.8) is trading above our estimate of fair value (₹4403.42)
Significantly Below Fair Value: 500488 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 500488 is poor value based on its PE Ratio (51.3x) compared to the IN Pharmaceuticals industry average (23x).
PE vs Market: 500488 is poor value based on its PE Ratio (51.3x) compared to the Indian market (16.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 500488's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 500488 is overvalued based on its PB Ratio (13.8x) compared to the IN Pharmaceuticals industry average (2.2x).
Next Steps
Future Growth
How is Abbott India forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
27.0%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Abbott India has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Check out Abbott India's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
- Abbott India competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Abbott India performed over the past 5 years?
21.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 500488 has high quality earnings.
Growing Profit Margin: 500488's current net profit margins (15.8%) are higher than last year (12.7%).
Past Earnings Growth Analysis
Earnings Trend: 500488's earnings have grown significantly by 21.1% per year over the past 5 years.
Accelerating Growth: 500488's earnings growth over the past year (35.2%) exceeds its 5-year average (21.1% per year).
Earnings vs Industry: 500488 earnings growth over the past year (35.2%) exceeded the Pharmaceuticals industry 14.7%.
Return on Equity
High ROE: 500488's Return on Equity (27%) is considered high.
Next Steps
Financial Health
How is Abbott India's financial position?
Financial Position Analysis
Short Term Liabilities: 500488's short term assets (₹32.0B) exceed its short term liabilities (₹8.9B).
Long Term Liabilities: 500488's short term assets (₹32.0B) exceed its long term liabilities (₹2.2B).
Debt to Equity History and Analysis
Debt Level: 500488's debt to equity ratio (0%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 500488's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 500488's debt is well covered by operating cash flow (27222134.8%).
Interest Coverage: 500488's interest payments on its debt are well covered by EBIT (69.1x coverage).
Balance Sheet
Next Steps
Dividend
What is Abbott India current dividend yield, its reliability and sustainability?
1.58%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 500488's dividend (1.58%) is higher than the bottom 25% of dividend payers in the Indian market (0.57%).
High Dividend: 500488's dividend (1.58%) is low compared to the top 25% of dividend payers in the Indian market (2.29%).
Stability and Growth of Payments
Stable Dividend: 500488's dividends per share have been stable in the past 10 years.
Growing Dividend: 500488's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (34.6%), 500488's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average board tenure
CEO
Anil Joseph (45 yo)
0.25
Tenure
Mr. Anil Joseph serves as Managing Director and Director at Abbott India Limited since July 01, 2020. He worked with reputable companies across different business sectors (predominately Healthcare & FMCG) ...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO & Whole-time Director | 3.17yrs | ₹33.00m | no data | |
| MD & Director | 0.25yr | no data | no data | |
| Additional Non Executive Non Independent Director | 4.08yrs | ₹71.50m | no data | |
| Chairman of the Board | 19.58yrs | ₹1.05m | no data | |
| Non-Executive Director | 9.58yrs | ₹15.90m | no data | |
| Independent Director | 1.5yrs | ₹1.20m | 0.0012% ₹ 4.0m | |
| Independent Director | 2.5yrs | ₹1.35m | no data | |
| Independent Director | 1yr | ₹550.00k | no data | |
| Additional Non-Executive Director | 0.083yr | no data | no data |
2.5yrs
Average Tenure
59yo
Average Age
Experienced Board: 500488's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Abbott India Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Abbott India Limited
- Ticker: 500488
- Exchange: BSE
- Founded: 1944
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹336.393b
- Shares outstanding: 21.25m
- Website: https://www.abbott.co.in
Number of Employees
Location
- Abbott India Limited
- Godrej BKC
- 16th Floor, Plot C, “G” Block
- Mumbai
- Maharashtra
- 400051
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 500488 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Sep 1999 |
| ABBOTINDIA | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Sep 1999 |
Biography
Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women’s health, gastroenterology, metabolics, central nervous sy ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/20 12:34 |
| End of Day Share Price | 2020/10/20 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.